Abstract
VCP/p97/Cdc48, a member of the ATPases associated with diverse cellular activities (AAA) family, is necessary for the endoplasmic-reticulum-associated protein degradation (ERAD) pathway to maintain protein homeostasis. Overwhelming proteotoxic stress drove cancer cells to enhance VCP/p97/Cdc48-associated ERAD to maintain protein homeostasis for survival, demonstrating that VCP/p97/Cdc48 expression was positively correlated with cancer prognosis. More studies revealed that targeting VCP/p97/Cdc48 could be a potential target in cancer therapy. CB-5083, a novel inhibitor of VCP/p97/Cdc48, is in clinical trials as the first VCP/p97/Cdc48- inhibiting drug for cancer therapy. Here, we discuss the relationship between VCP/p97/Cdc48, ERAD, protein homeostasis and cancer therapy.
Keywords: VCP/p97/Cdc48, protein homeostasis, ERAD, cancer therapy, ER stress, CB-5083.
Current Molecular Medicine
Title:VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy
Volume: 17 Issue: 9
Author(s): B. Lan, S. Chai, P. Wang*K. Wang*
Affiliation:
- Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,China
- Department of Respiratory Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou,China
Keywords: VCP/p97/Cdc48, protein homeostasis, ERAD, cancer therapy, ER stress, CB-5083.
Abstract: VCP/p97/Cdc48, a member of the ATPases associated with diverse cellular activities (AAA) family, is necessary for the endoplasmic-reticulum-associated protein degradation (ERAD) pathway to maintain protein homeostasis. Overwhelming proteotoxic stress drove cancer cells to enhance VCP/p97/Cdc48-associated ERAD to maintain protein homeostasis for survival, demonstrating that VCP/p97/Cdc48 expression was positively correlated with cancer prognosis. More studies revealed that targeting VCP/p97/Cdc48 could be a potential target in cancer therapy. CB-5083, a novel inhibitor of VCP/p97/Cdc48, is in clinical trials as the first VCP/p97/Cdc48- inhibiting drug for cancer therapy. Here, we discuss the relationship between VCP/p97/Cdc48, ERAD, protein homeostasis and cancer therapy.
Export Options
About this article
Cite this article as:
Lan B., Chai S. , Wang P. *, Wang K.*, VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy, Current Molecular Medicine 2017; 17 (9) . https://dx.doi.org/10.2174/1566524018666180308111238
DOI https://dx.doi.org/10.2174/1566524018666180308111238 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Current Medicinal Chemistry Inflammation and Chronic Oxidative Stress in Radiation-Induced Late Normal Tissue Injury: Therapeutic Implications
Current Medicinal Chemistry Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Preface [Hot Topic: Tuberous Sclerosis and Other Inherited Renal Cancer Syndromes: Lessons from the Eker Rat (Executive Editors: Laura S. Schmidt / Okio Hino)]
Current Molecular Medicine Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications
Current Drug Targets Impact on DNA Methylation in Cancer Prevention and Therapy by Bioactive Dietary Components
Current Medicinal Chemistry Bioinformatics and Drug Discovery
Current Topics in Medicinal Chemistry Catastrophic Antiphospholipid Syndrome - 20 Years Later
Current Rheumatology Reviews MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry Novel Concepts for Anti-Infective Activity of Cytokines, Chemokines and Diverse Agents
Recent Patents on Anti-Infective Drug Discovery A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It
Mini-Reviews in Medicinal Chemistry Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery Intraperitoneal Chemotherapy as First-Line Treatment in the Management of Epithelial Ovarian Cancer
Mini-Reviews in Medicinal Chemistry Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials
Current Drug Targets Application of Reproductive Hormone Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Current Drug Targets